A large, comparative, real-world study using AAO’s IRIS Registry evaluated 2-year outcomes among glaucoma patients receiving 3 different types of minimally invasive glaucoma surgery (MIGS). The study evaluated implant-free Omni Surgical System (Sight Sciences), Hydrus Microstent (Alcon), and iStent inject (Glaukos) combined with cataract surgery against cataract surgery alone. The results were presented at the 2023 European Society of Cataract and Refractive Surgery meeting in Vienna, Austria.

A total of 77,391 patients (109,745 eyes) were included; 6,632 patients (9,000 eyes) received a MIGS procedure with cataract surgery and the remainder had standalone cataract surgery. The primary outcomes were change in intraocular pressure (IOP) and the number of IOP-lowering medication classes, measured at 6, 12, 18, and 24 months. The patient population was homogenous and baseline characteristics were similar, according to a Sight Sciences news release.

At 24 months, patients treated with cataract surgery and MIGS showed greater medication reduction and greater IOP reduction compared to cataract surgery alone. Patients with baseline IOP >18 mmHg and Omni technology had the greatest numerical reduction in IOP and medication use. Patients with baseline IOP ≤18 mmHg who received Omni also had the greatest numerical reduction in IOP and a statistically significant greater mean medication reduction compared to all other treatment groups.